Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-05-15
2004-03-16
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S200000, C548S540000, C514S423000
Reexamination Certificate
active
06706742
ABSTRACT:
BACKGROUND OF THE INVENTION
Dipeptidyl peptidase IV is a membrane serine protease that is present in many human tissues and involved in numerous pathologies.
In particular, it has been shown that DPP IV is responsible for the inactivation of GLP-1 (glucagon-like peptide-1). GLP-1 is an important stimulator of the secretion of insulin in the pancreas and accordingly has a direct beneficial effect on the level of glucose in the blood.
Inhibition of DPP IV accordingly constitutes an extremely promising approach in the treatment of glucose intolerance and of disorders associated with hyperglycaemia, such as, for example, non-insulin-dependent diabetes (type II diabetes) or obesity.
DESCRIPTION OF THE PRIOR ART
DPP IV inhibitors have already been described in the literature, for example amide compounds in Patent Application EP 0 490 379 and in the journal Adv. Exp. Med. Biol. 1997, 421, 157-160, and carbamate compounds in Patent Application DE 19826972.
Moreover, &agr;-amino acid compounds, analogues of arginine, have been described in Patent Application WO 96/27593 as inhibitors of NO-synthase, for use, as such, in the treatment of pathologies of the central and peripheral nervous systems, pathologies of dysfunctions of the gastrointestinal and urinary systems, and pathologies associated with the cardiovascular or bronchopulmonary system.
The compounds of the invention have dipeptidyl peptidase IV-inhibiting properties, which thus makes them especially useful in the treatment of glucose intolerance and disorders associated with hyperglycaemia.
DETAILED DESCRIPTION OF THE INVENTION
More especially, the present invention relates to compounds of formula (I):
wherein:
represents a 5-membered nitrogen-containing heterocycle optionally substituted by a cyano group,
Ak represents a linear or branched (C
1
-C
6
)alkylene chain,
X represents a single bond or a phenylene group,
R
1
and R
2
, which may be identical or different, each represent a hydrogen atom or a linear or branched (C
1
-C
6
)alkyl group,
Y represents NR
4
or CH—NO
2
,
R
4
represents a hydrogen atom or a linear or branched (C
1
-C
6
)alkyl group,
R
3
represents:
a group selected from linear or branched (C
1
-C
6
)alkyl, nitro and cyano, when Y represents CH—NO
2
, or
a group selected from nitro and cyano, when Y represents NR
4
,
their tautomers when they exist, their optical isomers, and addition salts thereof with a pharmaceutically acceptable acid,
with the exclusion of compounds wherein, simultaneously,
represents an unsubstituted 5-membered nitrogen-containing heterocycle, Ak represents the group —(CH
2
)
3
—, X represents a single bond, Y represents NH and R
3
represents the nitro group.
Among the pharmaceutically acceptable acids, there may be mentioned by way of non-limiting example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, methanesulphonic acid, camphoric acid, oxalic acid, etc.
“5-membered nitrogen-containing heterocycle” is understood to mean a 5-membered saturated monocyclic group containing one, two or three hetero atoms, one of which hetero atoms is the nitrogen atom, and any additional hetero atoms present are selected from the atoms oxygen, nitrogen and sulphur.
The preferred 5-membered nitrogen-containing heterocycles are the groups pyrrolidinyl and thiazolidinyl.
The compounds of formula (I) wherein R
2
represents a hydrogen atom exist in two tautomeric forms represented by the formulae (Ia) and (Ib):
which both form an integral part of the invention.
The compounds of formula (I) wherein R
3
represents a hydrogen atom exist in two tautomeric forms represented by the formulae (Ic) and (Id):
which both form an integral part of the invention.
The preferred compounds of formula (I) are those wherein
represents a 1-pyrrolidinyl group optionally substituted by a cyano group, or a 1,3-thiazolidin-3-yl group optionally substituted by a cyano group.
The preferred compounds of formula (I) are those wherein the configuration &agr; to the amide function is (S).
An advantageous aspect of the invention relates to compounds of formula (I) wherein Ak represents the group (CH
2
)
4
.
Another advantageous aspect of the invention relates to compounds of formula (I) wherein
represents a 1-pyrrolidinyl group substituted by a cyano group, or a 1,3-thiazolidin-3-yl group substituted by a cyano group, and Ak represents the group (CH
2
)
3
.
A further advantageous aspect of the invention relates to compounds of formula (I) wherein X represents a single bond.
A further advantageous aspect of the invention relates to compounds of formula (I) wherein Y represents a group NR
4
, wherein R
4
represents a hydrogen atom or a linear or branched (C
1
-C
6
)alkyl group.
A further advantageous aspect of the invention relates to compounds of formula (I) wherein R
3
represents the nitro group.
Among the preferred compounds of the invention, there may be mentioned more especially:
N-{(4S)-4-amino-5-[(2S)-2-cyano-1-pyrrolidinyl]-5-oxopentyl}-N′-nitroguanidine, its tautomers, optical isomers, and addition salts thereof with a pharmaceutically acceptable acid,
N-{(5S)-5-amino-6-[(2S)-2-cyano-1-pyrrolidinyl]-6-oxohexyl}-N′-nitroguanidine, its tautomers, optical isomers, and addition salts thereof with a pharmaceutically acceptable acid, and
N-{(5S)-5-amino-6-(1,3-thiazolidin-3-yl)-6-oxohexyl}-N′-nitroguanidine, its tautomers, optical isomers, and addition salts thereof with a pharmaceutically acceptable acid.
The invention relates also to a process for the preparation of compounds of formula (I), characterised in that a compound of formula (II):
wherein Ak and X are as defined for formula (I), P
1
represents an amino-function-protecting group, and P
2
represents an amino-function-protecting group other than P
1
,
is reacted with a compound of formula (III):
wherein
is as defined for formula (I),
under conventional peptide coupling conditions, to yield, after deprotection, a compound of formula (IV),
wherein
P
1
, Ak and X are as defined hereinbefore,
which is then converted, by conventional organic chemistry reactions, followed by a deprotection reaction, to a compound of formula (I),
which is purified, if necessary, according to a conventional purification technique, separated, if desired, into its optical isomers according to a conventional separation technique, and converted, if desired, into addition salts thereof with a pharmaceutically acceptable acid.
The compounds of formula (Ie), a particular case of the compounds of formula (I):
wherein
R
1
, Ak and X are as defined for formula (I), can also be obtained starting from the compound of formula (V):
wherein P
1
, Ak and X are as defined hereinbefore, which is reacted with a compound of formula (III), under conventional peptide coupling conditions,
to yield, after deprotection where necessary, a compound of formula (Ie), which is purified, if necessary, according to a conventional purification technique, separated, if desired, into its optical isomers according to a conventional separation technique, and converted, if desired, into addition salts thereof with a pharmaceutically acceptable acid.
The compounds of the present invention, in addition to being new, have pharmacologically valuable properties. They have dipeptidyl peptidase IV-inhibiting properties which make them useful in the treatment of glucose intolerance and of disorders associated with hyperglycaemia, such as type II diabetes or obesity.
The invention relates also to pharmaceutical compositions comprising as active ingredient at least one compound of formula (I) with one or more suitable inert, non-toxic excipients. Among the pharmaceutical compositions according to the invention, there may be mentioned more especially those that are suitable for oral, parenteral (intravenous, intramuscular or subcutaneous) or nasal administration, tab
Benoist Alain
Boulanger Michelle
De Nanteuil Guillaume
Husson-Robert Bernadette
Levens Nigel
Les Laboratories Servier
McKane Joseph K.
Shameem Golam M
The Firm of Hueschen and Sage
LandOfFree
Alpha-amino-acid compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-amino-acid compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-amino-acid compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3266587